Grants and Contracts Details
Description
Alzheimer’s disease (AD) is a progressive neurologic disorder that is the most common cause
of dementia with devastating socioeconomic implications. More than 5 million people are
afflicted with AD and related dementias in the United States, and by 2050 this number could
rise as high as 16 million, with annual costs of over $1 trillion [1]. The emotional and financial
burden of AD to patients, family members, and society is enormous, and is predicted to grow
exponentially as the median population age increases. The potential to preserve, or even
improve, cognition in adults at high risk of cognitive decline due to AD clearly has important
implications, not only for the affected individual, but also for the support system that bears the
social and financial burdens of long-term caregiving.
Benfotiamine provides an important novel therapeutic direction in AD that has potential for
additive or synergistic effects beyond current mainstream approaches. It has a unique mechanism
of action, raising blood thiamine 50-100 times to pharmacological levels. In AD, it addresses and
treats a well-characterized tissue thiamine deficiency and related changes in glucose metabolism
as well as post-translational modifications including plaque [2] and tangle formation [3],
neuroinflammation [4, 5], neurodegeneration [6], and advanced glycation end products (AGEs)
[7]. Importantly, it further addresses the US National Alzheimer’s Project Act (NAPA)
therapeutic goal of combining targets [8].
Status | Active |
---|---|
Effective start/end date | 7/1/22 → 6/30/25 |
Funding
- University of California San Diego Health: $2.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.